A similar efficacy has been recently reported in a phase II study of the TYK2 inhibitor deucravacitinib in SLE; given that TYK2 mediates signalling from the type I IFN receptor, this provides further support to the fact that the IFN system is particularly important for skin disease in SLE, in light also of recent reports showing in situ IFN production from keratinocytes in lupus patients.38,39Post-hoc analyses from the TULIP trials suggest a beneficial effect in additional organ domains, and this remains to be proven also in real-life studies, which are eagerly awaited. Here, TYK2 is linked to systemic lupus erythematosus.